NCT05413044已完成不适用
A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 140,706 人开始时间: 2019年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140,706
- 试验地点
- 1
- 主要终点
- Incidence Rate of Basal Cell Carcinoma
研究概览
简要总结
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of RA or PsA
- •≥18 years at index treatment initiation
- •Participants starting treatment with:
- •abatacept
- •non-targeted DMARDs
- •targeted DMARD
排除标准
- •- Not applicable
结局指标
主要结局
Incidence Rate of Basal Cell Carcinoma
时间窗: 5 years
Incidence Rate of Overall Malignancies
时间窗: 5 years
Incidence Rate of Melanoma
时间窗: 5 years
Incidence Rate of Non-melanoma Skin Cancer
时间窗: 5 years
Incidence Rate of Squamous Cell Carcinoma
时间窗: 5 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South KoreaEssential HypertensionNCT04470817Celltrion Pharm, Inc.3,438
已完成
不适用
Safety Study of Abatacept in SwedenRheumatoid ArthritisNCT01094795Bristol-Myers Squibb92,635
已完成
不适用
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in KoreaHepatitis C VirusNCT02907996Gilead Sciences2,033
已完成
4 期
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenHaemophilus Influenzae Type B InfectionNCT01404962Novartis Vaccines764
已完成
不适用
A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South KoreaOvarian NeoplasmsNCT04589039Takeda662